QURE - uniQure N.V.
52.87 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 52.56 |
| Open | 52.69 |
| Bid | 52.78 x 900 |
| Ask | 52.84 x 1200 |
| Day's Range | 51.45 - 52.89 |
| 52 Week Range | 24.07 - 82.49 |
| Volume | 276,766 |
| Avg. Volume | 544,664 |
| Market Cap | 2.253B |
| Beta (3Y Monthly) | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.77 |
| Earnings Date | Oct 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 82.13 |
- Zacks
uniQure N.V. (QURE) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in uniQure N.V. (QURE).
- GlobeNewswire
uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- GlobeNewswire
uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 05, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- GlobeNewswire
uniQure to Participate in Multiple Upcoming Industry Conferences in November
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- GlobeNewswire
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances. With a combined follow-up of 78 weeks of observation on the three adult male participants with severe hemophilia B, the mean Factor IX (FIX) activity was 47 percent of normal (range of 33 percent to 57 percent of normal) following a single administration of etranacogene dezaparvovec (AMT-061).
- Simply Wall St.
Are Insiders Selling uniQure N.V. (NASDAQ:QURE) Stock?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- Zacks
UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of 30.12% and -53.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II.
- American City Business Journals
Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO
The Emeryville company says it has improved on the traditional way of delivering corrected copies of genes.
- Barrons.com
Biotech Roundtable: How to Invest in Medicine’s Future
As medical breakthroughs lead to revolutionary cures, the future looks bright for patients—and patient investors.
- Simply Wall St.
Is uniQure N.V.'s (NASDAQ:QURE) CEO Pay Justified?
In 2016 Matt Kapusta was appointed CEO of uniQure N.V. (NASDAQ:QURE). This analysis aims first to contrast CEO...
- GlobeNewswire
uniQure to Participate in Multiple Upcoming Industry Conferences in October
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- Insider Monkey
Hedge Fund P.A.W. Capital Partners’ Top Stock Picks
Peter A. Wright launched P.A.W. Capital Partners back in 1990. He is the fund’s Chief Investment Officer, General Partner and Senior Portfolio Manager ever since. He holds a BS in Chemical Engineering and an MBA from Cornell University. Mr. Wright started off his career at I.B.M, later moving to Gartner Group where he worked as an […]
- GlobeNewswire
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs today announced the pricing of its underwritten public offering of 4,891,305 of its ordinary shares at a public offering price of $46.00 per share. The gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by uniQure, are expected to be approximately $225 million. All ordinary shares to be sold in the offering are being sold by uniQure.
- Benzinga
The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 4) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Bioanalytical ...
- GlobeNewswire
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has commenced an underwritten public offering of $200 million of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to $30 million of additional ordinary shares at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
“We are extremely pleased to reach this important milestone in our ongoing development of etranacogene dezaparvovec, which we believe has the potential to be the first and best-in-class gene therapy for patients with hemophilia B,” stated Matt Kapusta, chief executive officer of uniQure.
- Simply Wall St.
uniQure (NASDAQ:QURE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
uniQure to Participate in Multiple Upcoming Industry Conferences in September
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
- GlobeNewswire
uniQure Announces Leadership Promotions and Executive Transition
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 20, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the promotions of Sander van Deventer, M.D., Ph.D., to Executive Vice President, Research and Product Development, and Alex Kuta, Ph.D., to Executive Vice President, Operations, effective immediately. As a result of these changes, the Company is eliminating the Chief Operating Officer role, and Scott McMillan, Ph.D., will be retiring from uniQure. “With the promotions of Sander and Alex, we are recognizing the demonstrated track-records and exceptional leadership that each has provided as we advance uniQure’s pipeline of novel gene therapies,” stated Matt Kapusta, chief executive officer of uniQure.
- Simply Wall St.
Introducing uniQure (NASDAQ:QURE), The Stock That Soared 653% In The Last Three Years
It might be of some concern to shareholders to see the uniQure N.V. (NASDAQ:QURE) share price down 22% in the last...
- Zacks
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -10.67% and 61.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
